US stocks are landing at Stockopedia Find out more
Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Jul 2008 2009 2010 2011 2012 2013 2014E 2015E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -3.6%

FINANCIAL BRIEF: For the fiscal year ended 31 July 2013, Avacta Group Plc revenues decreased 14% to L2.7M. Net loss increased 38% to L1.5M. Revenues reflect Analytical segment decrease of 27% to L1.2M. Higher net loss reflects Animal Health segment loss increase of 22% to L753K. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score
D-
D-

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Jul '13) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Jul 2014
31st Jul 2015

Price Target: 2.00 (+90.51% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (£) (£) (p) (£)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Avacta
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 2

Named Brokers and Analysts
Panmure Gordon Savvas Neophytou , Numis Securities Charles Weston , Equity Development Lorenza Castellon , Hume Capital Tim Freeborn ,

Avacta Group plc is a provider of technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. It is engaged in the research, development, production and delivery of instrumentation and services for the biopharmaceutical drug development and clinical diagnostics markets using biophysical technology. The Company has two segments: Analytical and Animal Health. The Analytical segment provides tools and contract services for early stage protein characterisation and analysis for biopharmaceutical drug developers. The Animal Health provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The Company’s subsidiaries include Avacta Limited, Avacta Analytical Limited, Oriental Fine Foods Limited, Avacta Health Limited, TheraGenetics Limited and TheraGenetics Inc.

Directors: Alastair Smith (CEO) , Timothy Sykes (CFO) , Craig Slater (COO) 50, Gwyn Humphreys (NEC) 66, Michael Albin (NED) 56, Trevor Nicholls (NED) 57, Alan Aubrey (NID) 52, Anthony Robards (NID) ,

No. of Employees: 73 No. of Shareholders: 0


Last Annual July 31st, 2013
Last Interim July 31st, 2013
Shares in Issue 4,967,649,550
ISIN GB0033519546
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

AVCT Share Price Performance AVCT Quote
0.935p
-0.1  -11.0%
Traded 4:06pm · Minimum 15 min delayed · NMS: 150k

Latest AVCT News Announcements (delayed)

Upcoming AVCT Events
No upcoming events.
Recent ↓
Wednesday 23rd April, 2014
Interim 2014 Avacta Group PLC Earnings Release
Wednesday 23rd April, 2014
Interim 2014 Avacta Group PLC Earnings Presentation (London)
Wednesday 5th February, 2014
Avacta Group PLC Investor Teach-in
Friday 24th January, 2014
Avacta Group PLC Annual General Meeting
Thursday 24th October, 2013
Preliminary 2013 Avacta Group PLC Earnings Presentation
Thursday 24th October, 2013
Preliminary 2013 Avacta Group PLC Earnings Release
Thursday 29th August, 2013
Avacta Group PLC Pre-Close Trading Update
Monday 5th August, 2013
Avacta Group PLC General Meeting
Thursday 18th July, 2013
Avacta Group PLC Secondary Public Offering Pricing
Tuesday 30th April, 2013
Interim 2013 Avacta Group PLC Earnings Presentation (London)


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.


Should you buy AVCT

Access AVCT Analytics Now!

FREE TRIAL or TAKE THE TOUR